Ibrutinib
ACCRU-LY-2001
Phase 2 small_molecule terminated
Quick answer
Ibrutinib for Asymptomatic COVID-19 Infection Laboratory-Confirmed is a Phase 2 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Asymptomatic COVID-19 Infection Laboratory-Confirmed
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated